Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0221002 (primary hyperparathyroidism)
 4,921 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pamidronate (aminopropylidene diphosphonate, APD) is known to be an effective agent in lowering plasma calcium in cancer associated hypercalcaemia and in primary hyperparathyroidism. Combined therapy with pamidronate and calcitonin has proved efficient in the treatment of severe cancer-associated hypercalcaemia. A 66-year-old woman in hypercalcaemic crisis caused by primary hypreparathyroidism was successfully treated with this combined therapy. Albumin corrected plasma calcium was 5.26 mmol/l on arrival and the PTH level was very high. The combined therapy lowered the plasma calcium to normal and made it possible to perform elective parathyreoidectomy. A 5.8 g parathyroid adenoma was removed. It is recommended to consider combined therapy with pamidronate and calcitonin in the emergency management of hypercalcaemic crisis.
 ...
PMID:[Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism]. 146 41

Recursive partitioning analysis was compared to logistic, linear and quadratic discriminant analyses in the ability to differentiate hypercalcemic patients with primary hyperparathyroidism from those with malignancy. Stepwise discriminant analysis identified serum albumin as the best single discriminant test. Albumin decision values optimally separating the two hypercalcemic groups were 39.46, 38.54, and 32.25 g/l for the logistic, linear and quadratic discriminant methods, respectively. Recursive partitioning analysis identified carboxy-terminus parathyroid hormone (PTH) as the best discriminant test with an optimal decision value of 8.2 mequiv/l. The discrepancy between the selection of PTH by recursive partitioning analysis and albumin by discriminant techniques was attributed to the nonnormal distribution of PTH. Recursive partitioning analysis using PTH classified 85.4% of the patients correctly. Logistic, linear and quadratic methods, using albumin as the predictor variable, correctly classified 79.6%, 78.6%, and 79.6% of patients, respectively.
 ...
PMID:Comparison of nonparametric recursive partitioning to parametric discriminant analyses in laboratory differentiation of hypercalcemia. 181 62

Mild hypercalcaemia associated with primary hyperparathyroidism has been increasingly recognized with the use of automated biochemical screening. Management is often difficult as symptoms are often absent or non-specific. Accordingly, we employed the hypocalcaemic effect of the diphosphonate APD to assess the effect of an acute fall in plasma calcium on indices of general well being, blood pressure, and vasoactive hormones in patients with mild primary hyperparathyroidism. Ten patients were studied in a randomized single blind, placebo-controlled cross-over study, using 30 mg APD intravenously or control saline infusion, over 2 h. Metabolic measurements, formal tests of muscle strength and cognitive function, and a standardized questionnaire were assessed 7 days after infusions. Albumin corrected plasma calcium was significantly lower (mean 2.49 +/- 0.04 SEM mmol/l) after APD when compared to control values (2.70 +/- 0.06 mmol/l, P less than 0.001). Twenty-four-hour urinary calcium, plasma magnesium and absolute monocyte count decreased significantly, whereas plasma parathyroid hormone increased after APD (P less than 0.05). There was no significant change in hypercalcaemic symptoms, muscle strength or cognitive function, and blood pressure, renin, aldosterone and atrial natriuretic peptide did not change. Side-effects, when they occurred, were mild. It is concluded that APD is a safe and effective means of lowering plasma calcium in mild primary hyperparathyroidism, but these acute reductions are associated with little or no improvement in clinical status in these patients.
 ...
PMID:Aminopropylidine diphosphonate (APD) in mild primary hyperparathyroidism: effect on clinical status. 218 63

The investigation of hypercalcemia is carried out routinely in our laboratory to detect primary hyperparathyroidism (PHPT). In a retrospective study, seven patients with PHPT and fifty-one patients with non-parathyroid hypercalcemia (NPHC) were chosen in a particular year. To obtain a screening index for PHPT, discriminant analysis, using a stepwise variable select method, was applied to eight biochemical parameters in these patients. A discriminant function (F1) was derived from three biochemical parameters and then another discriminant function (F2) was also derived from three biochemical parameters in the F1-positive patients. In combination of these two functions (F1 and F2), the final sensitivity was 100% and specificity was 98% in diagnosing PHPT. This screening method was tested prospectively in fifty-six consecutive specimens of hypercalcemia (PHPT 4, NPHC 52) over the following six months. The result was also satisfactory with a sensitivity of 100% and specificity of 98%. It was proven that our screening method using discriminant functions (F1 and F2) was very useful for diagnosing patients with PHPT from the survey of hypercalcemia. Among these patients with hypercalcemia, the high ratio (54%) of those with malignancy was remarkable. This interesting result required us to investigate potential hypercalcemia, since the serum calcium concentration was masked by a lower level of serum albumin, which was frequently seen in these malignant patients. As the next step, we tried to adjust the serum calcium concentration based on the serum albumin concentration. A formula for adjusting the calcium concentration was derived from a linear structural relationship between calcium and albumin in 6,821 specimens within a +/- 2.5 second principal component score in 7,021 consecutive specimens in whom both calcium and albumin were measured in a particular year; Adjusted Calcium = Calcium - Albumin + 4. After adjustment using this formula, the calcium concentrations were elevated above the upper limit of the reference interval in 320 of 5,203 specimens (6%) within the reference interval and elevated to the reference interval in 1,390 of 1,579 specimens (88%) below a lower limit of reference interval. A prospective study was performed over the following three months. Fifty patients with hypercalcemia were screened using this formula. It was a surprise that thirty-one patients (62%) showed abnormal values after adjustment. These results suggest that calcium adjustment is necessary for interpreting the calcium concentration of patients with a reduced albumin concentration such as patients with malignancy.
 ...
PMID:[Approach to examining hypercalcemia in the clinical laboratory]. 1063 24